Upregulated PARP1 confers breast cancer resistance to CDK4/6 inhibitors via YB-1 phosphorylation

Upregulated PARP1 confers breast cancer resistance to CDK4/6 inhibitors via YB-1 phosphorylation

Abstract Background Cyclic-dependent kinase (CDK) 4/6 kinases, as the critical drivers of the cell cycle, are involved in the tumor progression of various malignancies. Pharmacologic inhibitors of CDK4/6 have shown significant clinical prospects in treating hormone receptor-positive and human epider...

Full description

Bibliographic Details
Main Authors: Chuntao Quan, Zhijie Wu, Juan Xiong, Manqing Li, Yu Fu, Jiaying Su, Yue Wang, Lvwen Ning, Deju Zhang, Ni Xie
Format: Article
Language:English
Published: BMC 2023-11-01
Series:Experimental Hematology & Oncology
Subjects:
PARP1
CDK4/6 inhibitor
Drug resistance
YB-1
Cell cycle arrest
Online Access:https://doi.org/10.1186/s40164-023-00462-7

Internet

https://doi.org/10.1186/s40164-023-00462-7

Similar Items